{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:18:46Z","timestamp":1778685526936,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00520-026-10709-8","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:47:40Z","timestamp":1777398460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors"],"prefix":"10.1007","volume":"34","author":[{"given":"Noboru","family":"Morikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Okawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiko","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoki","family":"Sekikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Doshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michitoshi","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Mamesaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"10709_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"4","key":"10709_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"issue":"3","key":"10709_CR3","doi-asserted-by":"publisher","first-page":"C525","DOI":"10.1152\/ajpcell.00143.2024","volume":"327","author":"ACC Girardi","year":"2024","unstructured":"Girardi ACC, Polidoro JZ, Castro PC et al (2024) Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions. Am J Physiol Cell Physiol 327(3):C525\u2013C544. https:\/\/doi.org\/10.1152\/ajpcell.00143.2024","journal-title":"Am J Physiol Cell Physiol"},{"issue":"11","key":"10709_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7(11):845\u2013854. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10709_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3949\/ccjm.91a.23093","volume":"91","author":"R Jaswaney","year":"2024","unstructured":"Jaswaney R, Sokoloff S, Rakita V et al (2024) SGLT-2 inhibitors in heart failure and chronic kidney disease: a review for internists. Cleve Clin J Med 91(7):415\u2013423. https:\/\/doi.org\/10.3949\/ccjm.91a.23093","journal-title":"Cleve Clin J Med"},{"issue":"14","key":"10709_CR6","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1111\/1759-7714.14529","volume":"13","author":"T Miyawaki","year":"2022","unstructured":"Miyawaki T, Naito T, Doshita K et al (2022) Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer. Thorac Cancer 13(14):2064\u20132074. https:\/\/doi.org\/10.1111\/1759-7714.14529","journal-title":"Thorac Cancer"},{"issue":"1","key":"10709_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3795-2","volume":"17","author":"T Naito","year":"2017","unstructured":"Naito T, Okayama T, Aoyama T et al (2017) Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. BMC Cancer 17(1):800. https:\/\/doi.org\/10.1186\/s12885-017-3795-2","journal-title":"BMC Cancer"},{"key":"10709_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.2147\/JMDH.S311225","volume":"14","author":"Y Yonenaga","year":"2021","unstructured":"Yonenaga Y, Naito T, Okayama T et al (2021) Impact of physical inactivity on the risk of disability and hospitalization in older patients with advanced lung cancer. J Multidiscip Healthc 14:1521\u20131532. https:\/\/doi.org\/10.2147\/JMDH.S311225","journal-title":"J Multidiscip Healthc"},{"issue":"4","key":"10709_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4103\/apjon.apjon_20_18","volume":"5","author":"A Morikawa","year":"2018","unstructured":"Morikawa A, Naito T, Sugiyama M et al (2018) Impact of cancer cachexia on hospitalization-associated physical inactivity in elderly patients with advanced non-small-cell lung cancer. Asia Pac J Oncol Nurs 5(4):377\u2013382. https:\/\/doi.org\/10.4103\/apjon.apjon_20_18","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"6","key":"10709_CR10","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00520-014-2534-3","volume":"23","author":"M Kimura","year":"2015","unstructured":"Kimura M, Naito T, Kenmotsu H et al (2015) Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer 23(6):1699\u20131708. https:\/\/doi.org\/10.1007\/s00520-014-2534-3","journal-title":"Support Care Cancer"},{"issue":"5","key":"10709_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7","journal-title":"Lancet Oncol"},{"issue":"8","key":"10709_CR12","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41416-023-02177-2","volume":"128","author":"J Luo","year":"2023","unstructured":"Luo J, Hendryx M, Dong Y (2023) Sodium-glucose cotransporter 2 inhibitors and non-small cell lung cancer survival. Br J Cancer 128(8):1541\u20131547. https:\/\/doi.org\/10.1038\/s41416-023-02177-2","journal-title":"Br J Cancer"},{"key":"10709_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10709_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"12","key":"10709_CR15","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/dom.15249","volume":"25","author":"D Yabe","year":"2023","unstructured":"Yabe D, Shiki K, Homma G et al (2023) Efficacy and safety of empagliflozin in elderly Japanese adults with type 2 diabetes: a randomized, double-blind, placebo-controlled 52-week trial (EMPA-ELDERLY). Diabetes Obes Metab 25(12):3538\u20133548. https:\/\/doi.org\/10.1111\/dom.15249","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10709_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdi.12851","volume":"10","author":"T Sasaki","year":"2019","unstructured":"Sasaki T, Sugawara M, Fukuda M (2019) Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and metabolic profile: 52-week prospective LIGHT study. J Diabetes Investig 10(1):108\u2013117. https:\/\/doi.org\/10.1111\/jdi.12851","journal-title":"J Diabetes Investig"},{"issue":"8","key":"10709_CR17","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1007\/s00520-016-3156-8","volume":"24","author":"K Takayama","year":"2016","unstructured":"Takayama K, Atagi S, Imamura F et al (2016) Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients. Support Care Cancer 24(8):3473\u20133480. https:\/\/doi.org\/10.1007\/s00520-016-3156-8","journal-title":"Support Care Cancer"},{"issue":"1","key":"10709_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jcsm.12253","volume":"9","author":"DS Mytelka","year":"2018","unstructured":"Mytelka DS, Li L, Benoit K (2018) Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer. J Cachexia Sarcopenia Muscle 9(1):86\u201392. https:\/\/doi.org\/10.1002\/jcsm.12253","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"10709_CR19","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00520-021-06572-4","volume":"30","author":"T Miyawaki","year":"2022","unstructured":"Miyawaki T, Naito T, Yabe M et al (2022) Impact of weight loss on treatment with PD-1\/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. Support Care Cancer 30(2):1633\u20131641. https:\/\/doi.org\/10.1007\/s00520-021-06572-4","journal-title":"Support Care Cancer"},{"issue":"5","key":"10709_CR20","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1002\/jcsm.13323","volume":"14","author":"H Arai","year":"2023","unstructured":"Arai H, Maeda K, Wakabayash H et al (2023) Diagnosis and outcomes of cachexia in Asia: working consensus report from the Asian Working Group for Cachexia. J Cachexia Sarcopenia Muscle 14(5):1949\u20131958. https:\/\/doi.org\/10.1002\/jcsm.13323","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"10709_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188359","volume":"1873","author":"JA Siddiqui","year":"2020","unstructured":"Siddiqui JA, Pothuraju R, Jain M (2020) Advances in cancer cachexia: intersection between affected organs, mediators, and pharmacological interventions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1873(2):188359. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188359","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"15","key":"10709_CR22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"issue":"4","key":"10709_CR23","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/resp.12496","volume":"20","author":"JM Porcel","year":"2015","unstructured":"Porcel JM, Gasol A, Bielsa S et al (2015) Clinical features and survival of lung cancer patients with pleural effusions. Respirology 20(4):654\u2013659. https:\/\/doi.org\/10.1111\/resp.12496","journal-title":"Respirology"},{"issue":"9","key":"10709_CR24","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00424-020-02448-4","volume":"472","author":"EM Wright","year":"2020","unstructured":"Wright EM (2020) SGLT2 and cancer. Pflugers Arch 472(9):1407\u20131414. https:\/\/doi.org\/10.1007\/s00424-020-02448-4","journal-title":"Pflugers Arch"},{"issue":"21","key":"10709_CR25","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"issue":"6","key":"10709_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14061960","volume":"14","author":"LG Confederat","year":"2025","unstructured":"Confederat LG, Dragostin OM, Condurache MI (2025) SGLT2 inhibitors and the risk of urogenital infections: a concise review. J Clin Med 14(6):1960. https:\/\/doi.org\/10.3390\/jcm14061960","journal-title":"J Clin Med"},{"issue":"5","key":"10709_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14050264","volume":"14","author":"C Morace","year":"2024","unstructured":"Morace C, Lorello G, Bellone F et al (2024) Ketoacidosis and SGLT2 inhibitors: a narrative review. Metabolites 14(5):264. https:\/\/doi.org\/10.3390\/metabo14050264","journal-title":"Metabolites"},{"issue":"5","key":"10709_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003666","volume":"11","author":"E Chow","year":"2023","unstructured":"Chow E, Clement S, Garg R (2023) Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care 11(5):e003666. https:\/\/doi.org\/10.1136\/bmjdrc-2023-003666","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10709_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bja.2019.03.028","volume":"123","author":"V Thiruvenkatarajan","year":"2019","unstructured":"Thiruvenkatarajan V, Meyer EJ, Nanjappa N et al (2019) Perioperative diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors: a systematic review. Br J Anaesth 123(1):27\u201336. https:\/\/doi.org\/10.1016\/j.bja.2019.03.028","journal-title":"Br J Anaesth"},{"issue":"2","key":"10709_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15509","volume":"16","author":"T Oyakawa","year":"2025","unstructured":"Oyakawa T, Miura K, Muraoka N et al (2025) Sodium-glucose cotransporter 2 inhibitors for mesenchymal-epithelial transition inhibitor-induced edema. Thorac Cancer 16(2):e15509. https:\/\/doi.org\/10.1111\/1759-7714.15509","journal-title":"Thorac Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10709-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:48:02Z","timestamp":1778683682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10709-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10709"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10709-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8406171\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the Institutional Review Board of Shizuoka cancer center (Approval No. J2023-165\u20132023-2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for written informed consent was waived due to the retrospective nature of the study. Instead, an opt-out consent process was implemented, and patients were provided with the opportunity to decline participation. Details of the study were made publicly available to allow patients to opt out of participating.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Tateaki Naito has received research funding from Otsuka Pharmaceutical and the Japan Agency for Medical Research and Development (AMED) (to his institution) and honoraria from Ono Pharmaceutical and Helsinn SA. Hirotsugu Kenmotsu has received research grants from Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Eli Lilly K.K., AstraZeneca K.K., and Loxo Oncology (to his institution). He has also received honoraria for lectures or presentations from Amgen, AstraZeneca K.K., Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly K.K., Kyowa Kirin Co., Ltd., Merck, MSD, Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Pfizer, Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd.  Kazushige Wakuda has received research grants from Chugai Pharmaceutical Co., Ltd., AstraZeneca, Novartis, AbbVie, Amgen, MSD, Daiichi Sankyo, and Dizal Pharma (to his institution). He has received honoraria for lectures or presentations from several pharmaceutical companies including Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Ono Pharmaceutical, MSD, AstraZeneca, Daiichi Sankyo, Janssen Pharmaceutical, Takeda Pharmaceutical, and Nihon Kayaku.  Keita Miura has received honoraria for lectures or presentations from AstraZeneca, Chugai Pharmaceutical, and Taiho Pharmaceutical.  Nobuaki Mamesaya has received research funding from Boehringer Ingelheim (to his institution) and honoraria from Chugai Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Taiho Pharmaceutical, MSD, and Ono Pharmaceutical.  Ryo Ko has received research funding from MSD and AstraZeneca and honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, AstraZeneca, Ono Pharmaceutical, Daiichi Sankyo, Takeda, and MSD.  Toshiaki Takahashi has received research funding from multiple pharmaceutical companies including AstraZeneca, Eli Lilly, Chugai Pharmaceutical, MSD, Pfizer, Amgen, Merck Biopharma, Janssen Pharmaceutical, and AnHeart Therapeutics (to his institution), and honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, MSD, Pfizer, Takeda Pharmaceutical, Bristol-Myers Squibb, Amgen, and Novartis.  Akira Ono has received honoraria from AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical, and Indica Labs.  Haruki Kobayashi has received honoraria from Eli Lilly, Novartis Pharma, Taiho Pharmaceutical, AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, and Daiichi Sankyo.  Haruyasu Murakami has received research funding from several pharmaceutical companies including Chugai Pharmaceutical, AstraZeneca, Takeda, Daiichi Sankyo, AbbVie, IQVIA, Taiho Pharmaceutical, and Bayer (to his institution), honoraria from multiple pharmaceutical companies, and has served on advisory boards for Chugai Pharmaceutical, GAIA BioMedicine, Daiichi Sankyo, and Amgen.  All other authors declare that they have no competing interests.Hirotsugu Kenmotsu has received research grants from Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Eli Lilly K.K., AstraZeneca K.K., and Loxo Oncology (to his institution). He has also received honoraria for lectures or presentations from Amgen, AstraZeneca K.K., Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly K.K., Kyowa Kirin Co., Ltd., Merck, MSD, Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Pfizer, Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd.Kazushige Wakuda has received research grants from Chugai Pharmaceutical Co., Ltd., AstraZeneca, Novartis, AbbVie, Amgen, MSD, Daiichi Sankyo, and Dizal Pharma (to his institution). He has received honoraria for lectures or presentations from several pharmaceutical companies including Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Ono Pharmaceutical, MSD, AstraZeneca, Daiichi Sankyo, Janssen Pharmaceutical, Takeda Pharmaceutical, and Nihon Kayaku.Keita Miura has received honoraria for lectures or presentations from AstraZeneca, Chugai Pharmaceutical, and Taiho Pharmaceutical.Nobuaki Mamesaya has received research funding from Boehringer Ingelheim (to his institution) and honoraria from Chugai Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Taiho Pharmaceutical, MSD, and Ono Pharmaceutical.Ryo Ko has received research funding from MSD and AstraZeneca and honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, AstraZeneca, Ono Pharmaceutical, Daiichi Sankyo, Takeda, and MSD.Toshiaki Takahashi has received research funding from multiple pharmaceutical companies including AstraZeneca, Eli Lilly, Chugai Pharmaceutical, MSD, Pfizer, Amgen, Merck Biopharma, Janssen Pharmaceutical, and AnHeart Therapeutics (to his institution), and honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, MSD, Pfizer, Takeda Pharmaceutical, Bristol-Myers Squibb, Amgen, and Novartis.Akira Ono has received honoraria from AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical, and Indica Labs.Haruki Kobayashi has received honoraria from Eli Lilly, Novartis Pharma, Taiho Pharmaceutical, AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, and Daiichi Sankyo.Haruyasu Murakami has received research funding from several pharmaceutical companies including Chugai Pharmaceutical, AstraZeneca, Takeda, Daiichi Sankyo, AbbVie, IQVIA, Taiho Pharmaceutical, and Bayer (to his institution), honoraria from multiple pharmaceutical companies, and has served on advisory boards for Chugai Pharmaceutical, GAIA BioMedicine, Daiichi Sankyo, and Amgen.All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"472"}}